Danish pharmaceutical company Danske Zealand Pharma has taken a major step in capitalising on its diabetes product Lyxumia.
The Glostrup-based firm and its partner Sanofi has received approval for a US application for the composite product Lixilan.
Lixilan is a mixture of Danske Zealand Pharma’s Lyxumia and the world’s best-selling insulin, Lantus Sanofios.
Now that the application has been officially processed, the company will find out in August if its product has been approved.
“The US approval of the application is an important milestone in the regulatory process for this new type of diabetes drug,” said Danske Zealand Pharma head Britt Meelby Jensen.
Lyxumia is a GLP-1 analog that acts by stimulating the pancreatic production of insulin. It is the same type of product as Novo Nordisk’s Victoza, which earned 18 billion kroner in 2015.
Lyxumia as a single agent earned Dansk Zealand Pharma 21 million kroner in royalties in the first nine months of 2015.
The combination product Lixilan could help to considerably increase sales of Lyxumia.